期刊
CURRENT MEDICINAL CHEMISTRY
卷 18, 期 27, 页码 4152-4158出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/092986711797189592
关键词
Aptamers; cancer; intracellular kinases; SELEX; transmembrane kinases; RNA-bioconjugates
资金
- C.N.R., Association for International Cancer Research AICR [11-0075]
- MIUR
- MERIT [RBNE08YFN3_001]
- EU
- EMIL (European Molecular Imaging Laboratories Network) [503569]
- Worldwide Cancer Research [11-0075] Funding Source: researchfish
Deregulation of kinase function has been implicated in several important diseases, including cancer, neurological and metabolic disorders. Because of their key role in causing disease, kinases have become one of the most intensively pursued classes of drug targets. To date, several monoclonal antibodies (mAbs) and small-molecule inhibitors have been approved for the treatment of cancer. Aptamers are short structured single stranded RNA or DNA ligands that bind at high affinity to their target molecules and are now emerging as promising molecules to target specific cancer epitopes in clinical diagnosis and therapy. Further, because of their high specificity and low toxicity aptamers will likely reveal among the most promising molecules for in vivo targeted recognition as therapeutics or delivery agents for nanoparticles, small interfering RNAs bioconjugates, chemotherapeutic cargos and molecular imaging probes. In this article, we discuss recent advances in the development of aptamers targeting kinase proteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据